FI970115A0 - Nukeliinihappoja sisältävä valmiste, sen valmistus ja käytöt - Google Patents

Nukeliinihappoja sisältävä valmiste, sen valmistus ja käytöt

Info

Publication number
FI970115A0
FI970115A0 FI970115A FI970115A FI970115A0 FI 970115 A0 FI970115 A0 FI 970115A0 FI 970115 A FI970115 A FI 970115A FI 970115 A FI970115 A FI 970115A FI 970115 A0 FI970115 A0 FI 970115A0
Authority
FI
Finland
Prior art keywords
preparation
nucleic acids
pct
containing nucleic
date feb
Prior art date
Application number
FI970115A
Other languages
English (en)
Swedish (sv)
Other versions
FI119738B (fi
FI970115A (fi
Inventor
Jean-Paul Behr
Otmane Boussif
Barbara Demeneix
Franck Lezoualch
Mojgan Mergny
Daniel Scherman
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9465376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI970115(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI970115A publication Critical patent/FI970115A/fi
Publication of FI970115A0 publication Critical patent/FI970115A0/fi
Application granted granted Critical
Publication of FI119738B publication Critical patent/FI119738B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Polyamides (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
FI970115A 1994-07-13 1997-01-10 Nukleiinihapon liuosta ja kationisen polymeerin liuosta sisältävä koostumus ja käytöt FI119738B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9408735 1994-07-13
FR9408735A FR2722506B1 (fr) 1994-07-13 1994-07-13 Composition contenant des acides nucleiques, preparation et utilisations
FR9500914 1995-07-07
PCT/FR1995/000914 WO1996002655A1 (fr) 1994-07-13 1995-07-07 Composition contenant des acides nucleiques, preparation et utilisations

Publications (3)

Publication Number Publication Date
FI970115A FI970115A (fi) 1997-01-10
FI970115A0 true FI970115A0 (fi) 1997-01-10
FI119738B FI119738B (fi) 2009-02-27

Family

ID=9465376

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970115A FI119738B (fi) 1994-07-13 1997-01-10 Nukleiinihapon liuosta ja kationisen polymeerin liuosta sisältävä koostumus ja käytöt

Country Status (18)

Country Link
US (1) US6013240A (fi)
EP (1) EP0770140B1 (fi)
JP (1) JP4275728B2 (fi)
KR (1) KR100424802B1 (fi)
AT (1) ATE367448T1 (fi)
AU (1) AU2930795A (fi)
CA (1) CA2194797C (fi)
DE (1) DE69535540T9 (fi)
DK (1) DK0770140T3 (fi)
ES (1) ES2290952T3 (fi)
FI (1) FI119738B (fi)
FR (1) FR2722506B1 (fi)
IL (1) IL114566A (fi)
MX (1) MX9700270A (fi)
NO (1) NO323110B1 (fi)
PT (1) PT770140E (fi)
WO (1) WO1996002655A1 (fi)
ZA (1) ZA955849B (fi)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
ATE285477T1 (de) * 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
JP2001503041A (ja) * 1996-10-23 2001-03-06 エスケーダヴリュ トロストベルグ アクチエンゲゼルシャフト 生物活性ポリマーナノ粒子―核酸接合体の製造方法
EP0956001B1 (en) 1996-11-12 2012-09-12 The Regents of The University of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US6884430B1 (en) * 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
KR100615117B1 (ko) * 1997-09-15 2006-08-22 제네틱 이뮤너티, 엘엘씨. 피부의 항원제시 세포에 유전자를 전달하는 방법
DE19743135A1 (de) * 1997-09-30 1999-04-01 Hoechst Marion Roussel De Gmbh Biologisch verträgliche niedermolekular Polyethylenimine
JP2002518349A (ja) * 1998-06-18 2002-06-25 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン 核酸デリバリー用ポリマー
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
EP1044679B1 (en) * 1998-11-02 2012-12-26 Terumo Kabushiki Kaisha Stable Liposomes for Targeted Drug Delivery
US7160682B2 (en) * 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
RU2242970C2 (ru) * 1999-04-02 2004-12-27 Рисерч Дивелопмент Фаундейшн Композиции полиэтиленимин: днк для аэрозольной доставки
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
DE19960206A1 (de) * 1999-12-14 2001-07-19 Frank Czubayko Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung
JP2003518511A (ja) 1999-12-28 2003-06-10 トランジェーヌ、ソシエテ、アノニム ポリヌクレオチドを細胞へトランスフェクションするための組成物を調製するためのリチウム(Li+)の使用および遺伝子治療で有用な組成物
CA2395636A1 (en) * 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
FR2805271B1 (fr) * 2000-02-18 2002-04-26 Aventis Pharma Sa Procede de preparation de polyalkylenimines fonctionnalises, compositions les contenant et leurs utilisations
FR2813605B1 (fr) * 2000-09-05 2002-10-18 Aventis Pharma Sa Composes acidosensibles, leur preparation et utilisations
US20050085426A1 (en) * 2000-09-05 2005-04-21 Michel Bessodes Acid-sensitive compounds, preparation and use thereof
FR2814370B1 (fr) * 2000-09-22 2004-08-20 Centre Nat Rech Scient Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau
CN1479632A (zh) * 2000-10-09 2004-03-03 拜尔公司 用于将核酸导入细胞的复合物
DE10145134A1 (de) * 2000-10-09 2002-05-16 Bayer Ag Komplexe zur Einführung von Nukleinsäuren in Zellen
US20020091242A1 (en) 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
US20020187105A1 (en) * 2001-02-01 2002-12-12 Yiyu Zou Polymer combinations that result in stabilized aerosols for gene delivery to the lungs
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP1399189A1 (en) * 2001-06-11 2004-03-24 Universite De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
JP4516748B2 (ja) 2001-09-14 2010-08-04 サイトス バイオテクノロジー アーゲー ウィルス様粒子中への免疫賦活物質のパッケージ化:調製法および使用法
US20030138407A1 (en) * 2001-11-02 2003-07-24 Patrick Lu Therapeutic methods for nucleic acid delivery vehicles
CN1308643C (zh) 2002-01-17 2007-04-04 阿尔法·拉瓦尔股份公司 包括沉入式蒸发器的壳体
WO2003089618A2 (en) * 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
EP1507561B1 (en) 2002-05-24 2009-07-15 Mirus Bio Corporation Compositions for delivering nucleic acids to cells
DE60334618D1 (de) 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
MXPA05002791A (es) * 2002-09-13 2005-12-05 Replicor Inc Oligonucleotidos antivirales complementarios sin secuencia.
US10966421B2 (en) 2002-10-16 2021-04-06 Streck, Inc. Method and device for collecting and preserving cells for analysis
US7153905B2 (en) * 2003-03-21 2006-12-26 The General Hospital Corporation Hyperbranched dendron and methods of synthesis and use thereof
ES2559828T3 (es) 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
NZ581166A (en) 2003-09-15 2011-06-30 Protiva Biotherapeutics Inc Polyethyleneglycol-modified lipid compounds and uses thereof
WO2005085443A2 (en) * 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
WO2005089123A2 (en) * 2004-03-04 2005-09-29 Massachusetts Institute Of Technology Therapeutic anti-cancer dna
US20060026699A1 (en) * 2004-06-04 2006-02-02 Largaespada David A Methods and compositions for identification of genomic sequences
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
EP1773857A4 (en) 2004-07-02 2009-05-13 Protiva Biotherapeutics Inc THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF
AU2006308765B2 (en) 2005-11-02 2013-09-05 Arbutus Biopharma Corporation Modified siRNA molecules and uses thereof
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2009137911A1 (en) * 2008-05-15 2009-11-19 National Research Counsil Of Canada Process, vectors and engineered cell lines for enhanced large-scale transfection
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
CA2698812A1 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
EP2047858A1 (en) 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Combination products for treating cancer
DE102007056488A1 (de) 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
DE102008023913A1 (de) 2008-05-16 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
DE102008016275A1 (de) 2008-03-28 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
EP2363494A1 (de) 2007-11-22 2011-09-07 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
GB0724253D0 (en) * 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
JP5697988B2 (ja) 2007-12-27 2015-04-08 プロチバ バイオセラピューティクス インコーポレイティッド 干渉rnaを使用したポロ様キナーゼ発現のサイレンシング方法
US7687027B2 (en) * 2008-02-27 2010-03-30 Becton, Dickinson And Company Cleaning compositions, methods and materials for reducing nucleic acid contamination
FR2928373B1 (fr) * 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
WO2009129319A2 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
WO2009127060A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
EP2350043B9 (en) 2008-10-09 2014-08-20 TEKMIRA Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
US20100167271A1 (en) * 2008-12-30 2010-07-01 Streck, Inc. Method for screening blood using a preservative that may be in a substantially solid state form
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
DE102009006606A1 (de) 2009-01-29 2010-08-05 Philipps-Universität Marburg Nicht-virales Transfektionsmittel
DK3290530T3 (da) 2009-02-18 2020-12-07 Streck Inc Konservering af cellefrie nukleinsyrer
EP2623117A1 (en) 2009-04-30 2013-08-07 Genetic Immunity Kft. Immunogenic nanomedicine composition and preparation and uses thereof
IL292615B2 (en) 2009-07-01 2023-11-01 Protiva Biotherapeutics Inc Nucleic acid-lipid particles, preparations containing them and their uses
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9856456B2 (en) * 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
GB0917792D0 (en) 2009-10-12 2009-11-25 Fermentas Uab Delivery agent
WO2011057184A1 (en) * 2009-11-09 2011-05-12 Streck, Inc. Stabilization of rna in and extracting from intact cells within a blood sample
EP2549859B1 (en) 2010-03-24 2017-06-21 Institut National de la Santé et de la Recherche Medicale Primate model from the family Cercopithecidae infected by a HBV strain of human genotype
EP2552460A1 (en) 2010-03-29 2013-02-06 Universite De Strasbourg Polymers for delivering molecules of interest
WO2011160062A2 (en) 2010-06-17 2011-12-22 The Usa As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
EA023927B1 (ru) 2010-06-22 2016-07-29 Дна Терапьютикс ОПТИМИЗИРОВАННАЯ С ПОМОЩЬЮ ЭНДОСОМОЛИТИЧЕСКИХ СРЕДСТВ СИСТЕМА ДОСТАВКИ in vivo КОНЪЮГАТОВ НУКЛЕИНОВОЙ КИСЛОТЫ
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US20140234373A1 (en) 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance
EP2780456A1 (en) 2011-11-17 2014-09-24 The U.S.A. as represented by the Secretary, Department of Health and Human Services Therapeutic rna switches compositions and methods of use
CN109097398A (zh) 2011-11-24 2018-12-28 吉尼松公司 与工业制药应用相容的可放大的慢病毒载体生产系统
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP3800254A1 (en) * 2012-06-08 2021-04-07 Ethris GmbH Pulmonary delivery of messenger rna
CN103059295B (zh) * 2012-09-26 2016-01-13 上海交通大学 疏水修饰的聚乙烯亚胺及其作为蛋白质载体的用途
EP4085930A1 (en) 2012-10-05 2022-11-09 BioNTech Delivery Technologies GmbH Hydroxylated polyamine derivatives as transfection reagents for rna
US9677078B2 (en) 2012-10-08 2017-06-13 Lipocalyx Gmbh Carboxylated polyamine derivatives as transfection reagents
DE102012111891A1 (de) * 2012-12-06 2014-06-12 Eberhard Karls Universität Tübingen Medizinische Fakultät Verbesserung der Zielfindungskapazität von Stammzellen
ES2938048T3 (es) 2013-07-24 2023-04-04 Streck Llc Composiciones y procedimientos para estabilizar las células tumorales circulantes
WO2015073727A1 (en) 2013-11-13 2015-05-21 Aequus Biopharma, Inc. Engineered glycoproteins and uses thereof
WO2016054421A1 (en) 2014-10-02 2016-04-07 Protiva Biotherapeutics, Inc Compositions and methods for silencing hepatitis b virus gene expression
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
WO2016178233A1 (en) 2015-05-05 2016-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
EP3329003A2 (en) 2015-07-29 2018-06-06 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis b virus gene expression
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US10010627B2 (en) 2016-06-03 2018-07-03 International Business Machines Corporation Modified polycationic polymers
WO2018022991A1 (en) 2016-07-29 2018-02-01 Streck, Inc. Suspension composition for hematology analysis control
CA3044074A1 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
EP3570814B1 (en) 2017-01-19 2023-11-29 Universiteit Gent Molecular adjuvants for enhanced cytosolic delivery of active agents
BR112019022108A2 (pt) 2017-04-22 2020-05-12 Immunomic Therapeutics, Inc. Construções de lamp aprimoradas
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
EP3793595A1 (en) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
CN114641306A (zh) 2019-10-18 2022-06-17 免疫治疗有限公司 包含癌抗原的改良lamp构建物
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc calr and jak2 mutant-based vaccines and their uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4175721A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN112237633B (zh) * 2020-10-22 2023-06-27 林君玉 一种pei/on复合物及其制备方法和用途
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
GB202108176D0 (en) 2021-06-08 2021-07-21 Touchlight Ip Ltd Vector
KR20240024807A (ko) 2021-06-08 2024-02-26 터치라이트 아이피 리미티드 렌티바이러스 벡터
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993020090A1 (en) * 1992-04-06 1993-10-14 University Of Medicine & Dentistry Of New Jersey Paired-ion oligonucleotides and methods for preparing same
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids

Also Published As

Publication number Publication date
DE69535540T9 (de) 2012-03-15
WO1996002655A1 (fr) 1996-02-01
KR970704889A (ko) 1997-09-06
CA2194797C (fr) 2010-03-23
NO323110B1 (no) 2007-01-02
ATE367448T1 (de) 2007-08-15
DK0770140T3 (da) 2007-11-19
JPH10502918A (ja) 1998-03-17
FI119738B (fi) 2009-02-27
MX9700270A (es) 1997-05-31
US6013240A (en) 2000-01-11
FI970115A (fi) 1997-01-10
DE69535540D1 (de) 2007-08-30
FR2722506B1 (fr) 1996-08-14
PT770140E (pt) 2007-10-19
NO970049L (no) 1997-01-07
NO970049D0 (no) 1997-01-07
IL114566A0 (en) 1995-11-27
ZA955849B (en) 1996-02-21
ES2290952T3 (es) 2008-02-16
EP0770140B1 (fr) 2007-07-18
DE69535540T2 (de) 2008-06-19
KR100424802B1 (ko) 2004-06-23
AU2930795A (en) 1996-02-16
IL114566A (en) 2005-08-31
JP4275728B2 (ja) 2009-06-10
FR2722506A1 (fr) 1996-01-19
CA2194797A1 (fr) 1996-02-01
EP0770140A1 (fr) 1997-05-02

Similar Documents

Publication Publication Date Title
FI970115A (fi) Nukeliinihappoja sisältävä valmiste, sen valmistus ja käytöt
FI962799A0 (fi) Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
FR2715847B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
DE69829287D1 (de) Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens
FI973467A (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
NZ289720A (en) Nucleic acids coding for a telomerase, a ribonucleoprotein enzyme involved in telomere synthesis
BR9810369A (pt) Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
EP2172216A3 (en) Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP0957926A4 (en) OLIGONUCLEOTIDE COMPOSITION AND METHOD FOR REGULATING THE PROTEIN B7 EXPRESSION
ATE224736T1 (de) Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
DE69228997D1 (de) Menschliche il-3-varianten
HUT77029A (hu) A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk
BR9910787A (pt) Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src
HK1002658A1 (en) Imidazopyridine-azolidinones their preparation and pharmaceutical use
ATE221895T1 (de) Chimäre oligonucleotide und ihre verwendung
BR9712210A (pt) Processos de preparação de uma composição para a transferência de ácidos nucléicos e para a transferência de ácido nucléico em células in vitro ou ex vivo, e, composição para a transferência de ácidos nucléicos.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119738

Country of ref document: FI

MA Patent expired